Prognostic value of coexisting conditions and complications in pleuroparenchymal fibroelastosis: a single-center retrospective study
Main Article Content
Keywords
pleuroparenchymal fibroelastosis, PPFE, interstitial pneumonia, pulmonary fibrosis, hematopoietic stem cell transplantation, interstitial lung disease
Abstract
Background: Pleuroparenchymal fibroelastosis (PPFE) is a rare idiopathic interstitial lung disease (ILD) characterized by subpleural parenchymal fibrosis and elastosis mainly in the upper lobes. PPFE occurs in a secondary form that overlaps with underlying medical conditions or complications. This study evaluated the clinical impact of coexisting factors on the survival of patients with PPFE. Methods: Fifty-five PPFE patients were retrospectively evaluated. The patients’ diagnoses were categorized as “idiopathic PPFE” with no known cause or “secondary PPFE” with underlying medical conditions or complications. The clinical characteristics and survival rates of these groups were compared. Results: Twenty-eight patients (50.9%) were diagnosed with idiopathic PPFE and 27 (49.1%) with secondary PPFE, including cases of occupational dust exposure, connective tissue disease (CTD), post-hematopoietic stem cell transplantation (HSCT), and a family history of ILD. The idiopathic and secondary PPFE groups had similar clinical features, laboratory tests, and pulmonary function profiles, including a low body mass index, normal Krebs von den Lungen-6, high surfactant protein-D, and high residual volume/total lung capacity. In the secondary PPFE group, post-HSCT was associated with a worse prognosis, and CTD was associated with better prognosis. A multivariate analysis demonstrated that post-HSCT and a reduced forced vital capacity were significantly associated with a worsened survival in patients with PPFE. Conclusions: The prognosis of PPFE is highly influenced by underlying medical conditions or complications. Patients with post-HSCT PPFE should be monitored particularly closely, as they are at higher risk of a poor prognosis than others.
References
2. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-48.
3. Watanabe S, Waseda Y, Takato H, et al. Pleuroparenchymal fibroelastosis: Distinct pulmonary physiological features in nine patients. Respir Investig. 2015;53(4):149-55.
4. Watanabe K, Ishii H, Kiyomi F, et al. Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposal. Respir Investig. 2019;57(4):312-20.
5. Enomoto Y, Nakamura Y, Satake Y, et al. Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: A retrospective multicenter study. Respir Med. 2017;133:1-5.
6. Mariani F, Gatti B, Rocca A, et al. Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. Diagn Interv Radiol. 2016;22(5):400-6.
7. Orlandi M, Landini N, Bruni C, et al. Pleuroparenchymal fibroelastosis in rheumatic autoimmune diseases: a systematic literature review. Rheumatology (Oxford). 2020;59(12):3645-56.
8. Jacob J, Odink A, Brun AL, et al. Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis. Respir Med. 2018;138:95-101.
9. Xu L, Rassaei N, Caruso C. Pleuroparenchymal Fibroelastosis With Long History of Asbestos and Silicon Exposure. Int J Surg Pathol. 2018;26(2):190-3.
10. Watanabe K. Pleuroparenchymal Fibroelastosis: Its Clinical Characteristics. Curr Respir Med Rev. 2013;9(4):299-37.
11. Chua F, Desai SR, Nicholson AG, et al. Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics. Ann Am Thorac Soc. 2019;16(11):1351-9.
12. Kang J, Seo WJ, Lee EY, et al. Pleuroparenchymal fibroelastosis in rheumatoid arthritis-associated interstitial lung disease. Respir Res. 2022;23(1):143.
13. Sari A, Onder O, Armagan B, et al. Pleuroparenchymal fibroelastosis in systemic sclerosis-associated interstitial lung disease. Turk J Med Sci. 2022;52(1):83-8.
14. Gudmundsson E, Zhao A, Mogulkoc N, et al. Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment. EClinicalMedicine. 2021;38:101009.
15. Nakamura Y, Mori K, Enomoto Y, et al. Prognostic and Clinical Value of Cluster Analysis in Idiopathic Pleuroparenchymal Fibroelastosis Phenotypes. J Clin Med. 2021;10(7).
16. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-47.
17. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-8.
18. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
19. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68.
20. Harada T, Yoshida Y, Kitasato Y, et al. The thoracic cage becomes flattened in the progression of pleuroparenchymal fibroelastosis. Eur Respir Rev. 2014;23(132):263-6.
21. Ikeda T, Kinoshita Y, Ueda Y, Sasaki T, Kushima H, Ishii H. Physiological Criteria Are Useful for the Diagnosis of Idiopathic Pleuroparenchymal Fibroelastosis. J Clin Med. 2020;9(11).
22. Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265-75.
23. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452-8.
24. Kinoshita Y, Ikeda T, Miyamura T, et al. A proposed prognostic prediction score for pleuroparenchymal fibroelastosis. Respir Res. 2021;22(1):215.
25. Oda T, Sekine A, Tabata E, Iwasawa T, Takemura T, Ogura T. Comparison of Clinical Characteristics and Outcomes between Idiopathic and Secondary Pleuroparenchymal Fibroelastosis. J Clin Med. 2021;10(4).
26. Ikegami N, Nakajima N, Yoshizawa A, et al. Clinical, radiological and pathological features of idiopathic and secondary interstitial pneumonia with pleuroparenchymal fibroelastosis in patients undergoing lung transplantation. Histopathology. 2021.
27. Ishii H, Watanabe K, Kushima H, et al. Pleuroparenchymal fibroelastosis diagnosed by multidisciplinary discussions in Japan. Respir Med. 2018;141:190-7.
28. Namkoong H, Ishii M, Mori T, et al. Clinical and radiological characteristics of patients with late-onset severe restrictive lung defect after hematopoietic stem cell transplantation. BMC Pulm Med. 2017;17(1):123.
29. Oh SL, Lee JW, Yoo SY, et al. Pleuroparenchymal fibroelastosis after hematopoietic stem cell transplantation in children: a propensity score-matched analysis. Eur Radiol. 2023;33(3):2266-76.
30. von der Thüsen JH, Hansell DM, Tominaga M, et al. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol. 2011;24(12):1633-9.
31. Ishii T, Bandoh S, Kanaji N, et al. Air-leak Syndrome by Pleuroparenchymal Fibroelastosis after Bone Marrow Transplantation. Intern Med. 2016;55(2):105-11.
32. Matsui T, Maeda T, Kida T, et al. Pleuroparenchymal fibroelastosis after allogenic hematopoietic stem cell transplantation: important histological component of late-onset noninfectious pulmonary complication accompanied with recurrent pneumothorax. Int J Hematol. 2016;104(4):525-30.
33. Okimoto T, Tsubata Y, Hamaguchi M, Sutani A, Hamaguchi S, Isobe T. Pleuroparenchymal fibroelastosis after haematopoietic stem cell transplantation without graft-versus-host disease findings. Respirol Case Rep. 2018;6(3):e00298.
34. Murakami Y, Sakamoto K, Okumura Y, et al. Acute Exacerbation of Pleuroparenchymal Fibroelastosis Secondary to Allogenic Hematopoietic Stem Cell Transplantation. Intern Med. 2020;59(21):2737-43.
35. Higo H, Miyahara N, Taniguchi A, Maeda Y, Kiura K. Cause of pleuroparenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation. Respir Investig. 2019;57(4):321-4.
36. Shiiya H, Sato M. Lung Transplantation for Pleuroparenchymal Fibroelastosis. J Clin Med. 2021;10(5).
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
